Delving into the Latest Updates on ARG1 inhibitors(Molecure) with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Compound A17

Target

ARG1

Action

inhibitors

Mechanism

ARG1 inhibitors(Arginase-1 inhibitors)

Therapeutic Areas

NeoplasmsImmune System DiseasesCardiovascular Diseases+ [1]

Active Indication

AsthmaCardiovascular DiseasesNeoplasms

Inactive Indication-

Originator Organization

Molecure SA

Active Organization

Molecure SA

Inactive Organization-

Drug Highest PhasePreclinical

First Approval Date-

Regulation-

Inhibiting Arginase 1 (ARG1), a metalloenzyme that hydrolyzes l-arginine in the urea cycle, has been demonstrated as a promising therapeutic avenue in immuno-oncology through the restoration of suppressed immune response in several types of cancers. Most of the currently reported small molecule inhibitors are boronic acid based. Herein, we report the discovery of non-boronic acid ARG1 inhibitors through virtual screening. Biophysical and biochemical methods were used to experimentally profile the hits while X-ray crystallography confirmed a class of trisubstituted pyrrolidine derivatives as optimizable alternatives for the development of novel classes of immuno-oncology agents targeting this enzyme.

100 Deals associated with ARG1 inhibitors(Molecure)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Asthma	Preclinical	Poland	Molecure SA	15 Jan 2024
Cardiovascular Diseases	Preclinical	Poland	Molecure SA	15 Jan 2024
Neoplasms	Preclinical	Poland	Molecure SA	15 Jan 2024